[Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy]

Zhonghua Xue Ye Xue Za Zhi. 2019 Aug 14;40(8):693-696. doi: 10.3760/cma.j.issn.0253-2727.2019.08.016.

[Article in Chinese]

Authors

J Shi¹, K Sun, Z M Zhu, P C Lei, Z W Liu, Y Q Chen, J M Guo, Y Z Zang, J Yang, Y Zhang

Affiliation

¹ Department of Hematology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou 450003, China.

PMID: 31495142
PMCID: PMC7342872
DOI: 10.3760/cma.j.issn.0253-2727.2019.08.016

No abstract available

MeSH terms

Bortezomib / therapeutic use*
CD56 Antigen
Humans
Multiple Myeloma*
Prognosis
Proto-Oncogene Proteins c-kit

Substances

CD56 Antigen
Bortezomib
KIT protein, human
Proto-Oncogene Proteins c-kit

Grants and funding

基金项目：河南省医学科技攻关计划（201403154）